Fields Scott Z - North Shore Long Isl Jewish Hlth Syst, Hofstra North Shore LIJ Sch Med

基本信息

浏览量：5

职业迁徙

个人简介

暂无内容

研究兴趣

论文共 30 篇作者统计合作学者相似作者

按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选

Clinical Activity and Safety of Naptumomab Estafenatox (NAP) and Docetaxel in Patients (pts) with Checkpoint Inhibitor (CPI) –pretreated Advanced/metastatic Non-Small Cell Lung Cancer (NSCLC): Preliminary Results of a P2 Trial

Timothy Larson,Robert M. Jotte, Ahmed Mohammed Fouad Abdelaziz,Kartik Konduri,Donald A. Richards, Michael W. Meshad,Govardhanan Nagaiah, Alexander I. Spira,Pankaj Khandelwal, Ilana Lorber,Tal Hetzroni Kedem, Marcel Rozencweig,Scott Z. Fields

JOURNAL OF CLINICAL ONCOLOGYno. 16 (2024)

引用0浏览0引用

Safety and Preliminary Activity of Naptumomab Estafenatox (NAP) and Durvalumab in Patients with Advanced or Metastatic Solid Tumors: Interim Results from a Phase 1b Trial

Ravit Geva,Salomon Stemmer,Ruth Perets,Corinne Maurice-Dror,Eitan Ben-Ami,Ari Raphael, Sanjeev Kumar, Ilana Lorber,Tal Hetzroni Kedem,Scott Z. Fields, Marcel Rozencweig,Talia Golan

CANCER RESEARCHno. 8 (2023)

引用0浏览0引用

Abstract CT205: Safety and Preliminary Activity of Naptumomab Estafenatox (NAP) and Durvalumab in Patients with Advanced or Metastatic Solid Tumors: Interim Results from a Phase 1b Trial

Ravit Geva,Salomon Stemmer,Ruth Perets,Corinne Maurice-Dror,Eitan Ben-Ami,Ari Raphael,Sanjeev Kumar, Ilana Lorber,Tal Hetzroni Kedem,Scott Z. Fields,Marcel Rozencweig,Talia Golan

Cancer Research（2023）

引用0浏览0引用

Phase 1b Multi-Indication Study of the Antibody Drug Conjugate Anetumab Ravtansine in Patients with Mesothelin-Expressing Advanced or Recurrent Malignancies

Alex A. Adjei,Tanios S. Bekaii-Saab,Jordan Berlin, Philip,Teresa Macarulla Mercade,Annette Walter,Lisa Cupit,Rong Liu,Scott Z. Fields,Ariadna Holynskyj

Journal of clinical oncology（2018）

引用8浏览0引用

Atr Inhibitor M6620 (Formerly Vx-970) With Cisplatin In Metastatic Triple-Negative Breast Cancer: Preliminary Results From A Phase 1 Dose Expansion Cohort (Nct02157792)

Ml Telli,S Lord,Emma Dean, Abramson,H-T Arkenau,C Murias,C Becerra,R Tang,Marina Penney,John Pollard,G Conboy,Scott Z. Fields,Geoffrey I. Shapiro,Sara M. Tolaney

CANCER RESEARCH（2018）

引用4浏览0引用

Preclinical Characterization Of Vx-984, A Selective Dna-Dependent Protein Kinase (Dna-Pk) Inhibitor In Combination With Doxorubicin In Breast And Ovarian Cancers

Diane M. Boucher,David Newsome,Darin Takemoto,Shawn Hillier,Yuxin Wang,R Arimoto,John Maxwell,Paul S. Charifson,Scott Z. Fields,Kirk Tanner, Penney

CANCER RESEARCH（2017）

引用4浏览0引用

Abstract CT012: Phase 1 Trial of First-in-class ATR Inhibitor VX-970 in Combination with Cisplatin (cis) in Patients (pts) with Advanced Solid Tumors (NCT02157792)

Geoffrey Shapiro,Robert Wesolowski,Mark Middleton,Craig Devoe,Anastasia Constantinidou,Dionysis Papadatos-Pastos, Marjorie Fricano,Yanqiong Zhang,Sharon Karan,John Pollard,Marina Penney,Mohammed Asmal, F. Gary Renshaw,Scott Z. Fields,Timothy A. Yap

Cancer research（2016）

引用13浏览0引用

PK/PD modeling predicts robust target engagement and low probability of grade 4 hematological toxicity at recommended phase 2 starting dose of VX-970 in combination with carboplatin (AUC=5)

Brian Hare,Eric Haseltine,Marina Penney, Lakshmi Viswanathan,Jessica Brown,Mahesha Ganegoda,John Pollard, Tim Yap,Scott Z. Fields

JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS（2016）

引用0浏览0引用

Phase I Trial of First-In-Class Atr Inhibitor Vx-970 in Combination with Gemcitabine (gem) in Advanced Solid Tumors (Nct02157792)

Elizabeth R. Plummer,Emma Jane Dean,T. R. Jeffry Evans,Alastair Greystoke,Karin Herbschleb,Malcolm Ranson,Jennifer Brown,Yanqiong Zhang,Sharon Karan,John Pollard,Marina S. Penney,Mohammed Asmal,Scott Z. Fields,Mark R. Middleton

Journal of clinical oncology（2016）

引用30浏览0引用

加载更多

作者统计

合作学者

合作机构

D-Core

合作者
学生
导师

暂无相似学者，你可以通过学者研究领域进行搜索筛选

数据免责声明

页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果，我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问，可以通过电子邮件方式联系我们：report@aminer.cn